Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Global pharma major Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Tenofovir Alafenamide Tablets, 25 mg, to market a generic equivalent of Vemlidy® Tablets, 25 mg, of Gilead Sciences, Inc. (Gilead). This product will be manufactured at Lupin's Nagpur facility in India.
Tenofovir Alafenamide Tablets (RLD: Vemlidy® Tablets) had estimated annual sales of USD 484.2 million in the U.S. (IQVIA MAT December 2021).
Subscribe to PharmaTutor News Alerts by Email
